Vivani Medical Partners with Novo Nordisk on NPM-139
ALAMEDA, Calif., July 7, 2026 Vivani Medical, Inc. has entered into a new strategic agreement with Novo Nordisk to...
Novo Nordisk
Advertisement
Novo Nordisk Showcases New Hemophilia Data Featuring Denecimig at ISTH 2026
PLAINSBORO, N.J., and BAGSVÆRD, Denmark, June 26, 2026 Novo Nordisk announced it will present new clinical and scientific findings...
5W AI Index Reveals New Pharma Visibility Leaders Online
BOCA RATON, Fla., June 19, 2026 5W AI Communications has released its Pharma / Rx AI Visibility Index 2026,...
Novo Nordisk Secures UK Approval for First Wegovy Weight-Loss Pill
BAGSVÆRD, Denmark, June 11, 2026 Novo Nordisk announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has...
Novo Nordisk’s CagriSema Delivers Strong HbA1c and Weight Loss Results in Phase 3 REIMAGINE Trials
Plainsboro, New Jersey and Bagsværd, Denmark, June 7, 2026 Novo Nordisk has unveiled compelling Phase 3 clinical data for...
Advertisements
Novo Nordisk Reports Strong Phase 2 Zenagamtide Data
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 6, 2026 Novo Nordisk has announced positive results from a Phase 2 clinical...
Novo Nordisk Launches Wegovy Pill in UAE Market
BAGSVÆRD, Denmark, June 3, 2026 Novo Nordisk has announced the launch of Wegovy® pill (semaglutide tablets) in the United...
Novo Nordisk’s Wegovy 7.2 mg Wins CHMP Support
BAGSVÆRD, Denmark, May 22, 2026 Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
Novo Nordisk Expands Wegovy Leadership at ECO 2026
BAGSVAERD, Denmark, May 12, 2026 Novo Nordisk announced new clinical findings at the 2026 European Congress on Obesity (ECO...
Novo Nordisk Reports 28% Weight Loss With Higher-Dose Wegovy
Bagsværd, Denmark, May 12, 2026 Novo Nordisk presented new analyses from its pivotal STEP UP clinical trial at the...
Advertisement
